The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.45, representing a -0.3% change from its previous close.

Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), retaining the price target of ...

Viking Therapeutics (VKTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Viking Therapeutics Inc. on Wednesday reported positive data from an early-stage trial of a treatment for the rare, and often ...

We recently compiled a list of the 10 Best Hot Stocks To Buy Right Now. In this article, we are going to take a look at where ...

The market could potentially see the emergence of new biotech industry leaders. Since the year started, Viking Therapeutics ...

Viking Therapeutics (NASDAQ: VKTX) has captured the attention of investors, with its stock price skyrocketing over 400% in ...

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $64.96, denoting a +1.33% change from the preceding trading day.

On Monday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $63.01 which represents a decrease of $-1.95 or -3.00% from the prior close of $64.96. The stock opened at $65.61 and ...

One of the current stars of the biotech world is Viking Therapeutics (NASDAQ: VKTX), and for good reason. The clinical-stage company is advancing to the later stages of developing a drug that, if ...

On Wednesday, Viking Therapeutics Inc. (NASDAQ:VKTX) released data from the Phase 1b trial of VK0214, a novel small molecule ...